{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:05:57Z","timestamp":1790751957120,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.ymgme.2005.03.010","type":"journal-article","created":{"date-parts":[[2005,5,11]],"date-time":"2005-05-11T07:53:47Z","timestamp":1115798027000},"page":"247-254","source":"Crossref","is-referenced-by-count":94,"title":["Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease"],"prefix":"10.1016","volume":"85","author":[{"given":"Yan","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Millington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Amalfitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyanira","family":"Corzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Tsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2005.03.010_bib1","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgme.2005.03.010_bib2","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","article-title":"Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease","volume":"87","author":"Barton","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2005.03.010_bib3","first-page":"A25","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"68","author":"Kakkis","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2005.03.010_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2005.03.010_bib5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1432-1033.1995.903_a.x","article-title":"Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase","volume":"234","author":"Fuller","year":"1995","journal-title":"Eur. J. Biochem ."},{"key":"10.1016\/j.ymgme.2005.03.010_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1073\/pnas.93.1.65","article-title":"High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease","volume":"93","author":"Van Hove","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2005.03.010_bib7","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/hmg\/7.11.1815","article-title":"Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice","volume":"7","author":"Bijvoet","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2005.03.010_bib8","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/hmg\/8.12.2145","article-title":"Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II","volume":"8","author":"Bijvoet","year":"1999","journal-title":"Hum. Mol. Genet ."},{"key":"10.1016\/j.ymgme.2005.03.010_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI1722","article-title":"Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail","volume":"101","author":"Kikuchi","year":"1998","journal-title":"J. Clin. Invest ."},{"key":"10.1016\/j.ymgme.2005.03.010_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00125817-200103000-00008","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2005.03.010_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2005.03.010_bib12","first-page":"259A","article-title":"Enzyme replacement therapy with recombinant human acid alpha glucosidase (rhGAA) in infantile Pompe disease (IPD): results from a Phase 2 study","volume":"53","author":"Kishnani","year":"2002","journal-title":"Pediatr. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2005.03.010_bib13","first-page":"186","article-title":"Enzyme replacement therapy (ERT) in infantile-onset Pompe disease (IOPD): long term follow-up results","volume":"27","author":"Kishnani","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2005.03.010_bib14","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2005.03.010_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe\u2019s disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2005.03.010_bib16","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease-type II after hepatic targeting of a modified adenovirus vector encoding human acid-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2005.03.010_bib17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/mthe.2002.0563","article-title":"Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent upon vector dose, transgene promoter, and the tissues targeted for vector transduction","volume":"5","author":"Ding","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2005.03.010_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/jgm.355","article-title":"Multiple muscles in the AMD quail can be \u201ccross-corrected\u201d of pathologic glycogen accumulation after intravenous injection of an [E1-,polymerase-] adenovirus vector encoding human acid-alpha-glucosidase","volume":"5","author":"McVie-Wylie","year":"2003","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymgme.2005.03.010_bib19","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/sj.gt.3302314","article-title":"Improved efficacy of gene therapy approaches for Pompe disease using a new, immune deficient GSD-II mouse model","volume":"11","author":"Xu","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2005.03.010_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8 pseudotyped (AAV2\/8) vector in glycogen storage disease type II (GSD-II)","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2005.03.010_bib21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2362.1974.tb02358.x","article-title":"Increased excretion of a glucose-containing tetrasaccharide in the urine of a patient with glycogen storage disease type II (Pompe\u2019s disease)","volume":"4","author":"Hallgren","year":"1974","journal-title":"Eur. J. Clin. Invest ."},{"key":"10.1016\/j.ymgme.2005.03.010_bib22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0140-6736(83)92122-0","article-title":"Increased urinary excretion of a glycogen-derived tetrasaccharide in heterozygotes with glycogen storage diseases type II and III","volume":"1","author":"Chester","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2005.03.010_bib23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/clinchem\/40.6.914","article-title":"HPLC analysis of oligosaccharides in urine from oligosaccharidosis patients","volume":"40","author":"Peelen","year":"1994","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2005.03.010_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/abio.2000.4838","article-title":"Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease","volume":"87","author":"An","year":"2000","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2005.03.010_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/clinchem\/48.1.131","article-title":"Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry","volume":"48","author":"Rozaklis","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2005.03.010_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2005.03.010_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/abio.1998.3021","article-title":"Analysis of sialyllactoses in blood and urine by high-performance liquid chromatography","volume":"269","author":"Fu","year":"1999","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2005.03.010_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mus.10381","article-title":"Morphological changes in muscle tissue of patients with infantile Pompe\u2019s disease receiving enzyme replacement therapy","volume":"27","author":"Winkel","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2005.03.010_bib29","first-page":"27","article-title":"Studies on the metabolic origin of a glucose-containing tetrasaccharide in human urine","volume":"1","author":"Ugorski","year":"1983","journal-title":"J. Exp. Pathol."},{"key":"10.1016\/j.ymgme.2005.03.010_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0009-8981(88)90172-6","article-title":"Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen","volume":"176","author":"Kumlien","year":"1988","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2005.03.010_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(02)02491-2","article-title":"Synthesis of novel internal standards in the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry","volume":"515","author":"Mills","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2005.03.010_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"for the international Fabry Disease Study Group, Long-Term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2005.03.010_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2005.03.010_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2005.03.010_bib35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1203\/01.PDR.0000113789.30640.5C","article-title":"Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry","volume":"55","author":"Crawley","year":"2004","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2005.03.010_bib36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"144","author":"Harmatz","year":"2004","journal-title":"J. Pediatr."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719205001101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719205001101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T05:18:00Z","timestamp":1586236680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719205001101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S1096719205001101"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2005.03.010","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}